Menu Search
Equities

Alnylam Pharmaceuticals Inc

DUL:HAN

Alnylam Pharmaceuticals Inc

Actions
  • Price (EUR)255.20
  • Today's Change4.10 / 1.63%
  • Shares traded--
  • 1 Year change+61.31%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 16:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

  • Revenue in USD (TTM)2.09bn
  • Net income in USD-332.26m
  • Incorporated2003
  • Employees2.10k
  • Location
    Alnylam Pharmaceuticals Inc675 W Kendall StCAMBRIDGE 02142-1168United StatesUSA
  • Phone+1 (617) 551-8200
  • Fax+1 (617) 551-8101
  • Websitehttps://www.alnylam.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.